Phaseline

Companies › CSPC Baike (Shandong) Biopharmaceutical

CSPC Baike (Shandong) Biopharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Metabolic and endocrine, Respiratory; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CM326
unclear - code-named drug
–Phase 3Moderate to Severe AsthmaDec 2028
SYH9017
GLP-1 receptor agonist
–Phase 1Overweight or Obesity–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06830343SYH9017Phase 1Overweight or ObesityMetabolic and endocrineAug 2026
NCT07372287CM326Phase 3Moderate to Severe AsthmaRespiratoryDec 2028

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

BrightGene Bio-Medical Technology Chiesi Farmaceutici JCR Pharmaceuticals Viking Therapeutics Aphaia Pharma US

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.